NZ616035A - Compositions relating to a mutant clostridium difficile toxin and methods thereof - Google Patents

Compositions relating to a mutant clostridium difficile toxin and methods thereof Download PDF

Info

Publication number
NZ616035A
NZ616035A NZ616035A NZ61603512A NZ616035A NZ 616035 A NZ616035 A NZ 616035A NZ 616035 A NZ616035 A NZ 616035A NZ 61603512 A NZ61603512 A NZ 61603512A NZ 616035 A NZ616035 A NZ 616035A
Authority
NZ
New Zealand
Prior art keywords
clostridium difficile
amino acid
difficile toxin
mutation
methods
Prior art date
Application number
NZ616035A
Other languages
English (en)
Inventor
Maninder K Sidhu
Annaliesa Sybil Anderson
Robert G K Donald
Kathrin Ute Jansen
Narender K Kalyan
Terri L Mininni
Justin Keith Moran
Mark E Ruppen
Michael James Flint
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of NZ616035A publication Critical patent/NZ616035A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ616035A 2011-04-22 2012-04-20 Compositions relating to a mutant clostridium difficile toxin and methods thereof NZ616035A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478474P 2011-04-22 2011-04-22
US201161478899P 2011-04-25 2011-04-25
PCT/IB2012/051999 WO2012143902A1 (en) 2011-04-22 2012-04-20 Compositions relating to a mutant clostridium difficile toxin and methods thereof

Publications (1)

Publication Number Publication Date
NZ616035A true NZ616035A (en) 2016-03-31

Family

ID=46085103

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ616035A NZ616035A (en) 2011-04-22 2012-04-20 Compositions relating to a mutant clostridium difficile toxin and methods thereof

Country Status (30)

Country Link
US (13) US8481692B2 (enExample)
EP (4) EP3505531B1 (enExample)
JP (8) JP5917682B2 (enExample)
KR (1) KR101667837B1 (enExample)
CN (3) CN107022532B (enExample)
AR (1) AR086199A1 (enExample)
AU (6) AU2012245904B2 (enExample)
BR (2) BR112013027229B1 (enExample)
CA (1) CA2832712C (enExample)
CO (1) CO6801643A2 (enExample)
DK (2) DK2699587T3 (enExample)
ES (3) ES2742823T3 (enExample)
FI (1) FI3549949T3 (enExample)
HR (2) HRP20240042T1 (enExample)
HU (2) HUE047085T2 (enExample)
IL (8) IL270779B2 (enExample)
MX (3) MX391236B (enExample)
MY (2) MY182429A (enExample)
NZ (1) NZ616035A (enExample)
PE (2) PE20141029A1 (enExample)
PH (1) PH12013502178B1 (enExample)
PL (3) PL3505531T3 (enExample)
PT (2) PT2699587T (enExample)
RU (2) RU2592686C2 (enExample)
SA (3) SA115360698B1 (enExample)
SG (3) SG10201911993UA (enExample)
SI (3) SI3549949T1 (enExample)
TW (6) TWI815599B (enExample)
WO (1) WO2012143902A1 (enExample)
ZA (1) ZA201307818B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
CA2745096C (en) * 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
CN103957931B (zh) * 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
TWI815599B (zh) * 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
CN103974718A (zh) * 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US20140081659A1 (en) 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CA2890166C (en) * 2012-11-06 2023-08-15 Bayer Pharma Aktiengesellschaft Formulation for bispecific t-cell engagers (bites)
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
JP2016518374A (ja) * 2013-04-22 2016-06-23 ボード オブ リージェンツ オブ ザ ユニバーシテイ オブ オクラホマ クロストリジウム・ディフィシルワクチン及び使用方法
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
CA2954087C (en) * 2014-07-25 2023-09-19 Biosynth S.R.L. Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
US11434264B2 (en) * 2015-02-13 2022-09-06 Quanterix Corporation Immunoassays for differential detection of clostridium difficile
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
US20190211377A1 (en) * 2016-12-22 2019-07-11 Roche Molecular Systems, Inc. Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile
EP3687570A1 (en) * 2017-09-28 2020-08-05 Pfizer Inc Compositions and methods for eliciting an immune response against clostridium difficile
EP3946444A1 (en) * 2019-04-01 2022-02-09 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
US12343388B2 (en) 2019-05-10 2025-07-01 The Board Of Regents Of The University Of Oklahoma Clostridioides difficile TcdB variants, vaccines and methods of use
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
WO2021226330A1 (en) * 2020-05-06 2021-11-11 Albert Einstein College Of Medicine Agents to prevent tissue damage from clostridium difficile infections by inhibition of the gut-damaging bacterial toxins tcda and tcdb
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN111755068B (zh) * 2020-06-19 2021-02-19 深圳吉因加医学检验实验室 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置
EP4493153A1 (en) 2022-03-14 2025-01-22 Pfizer Inc. Methods for producing an adjuvant
EP4531899A1 (en) 2022-06-01 2025-04-09 Valneva Austria GmbH Clostridium difficile vaccine
JP2025541207A (ja) 2022-12-13 2025-12-18 ファイザー・インク クロストリディオイデス（クロストリジウム）・ディフィシル（ｃｌｏｓｔｒｉｄｉｏｉｄｅｓ（ｃｌｏｓｔｒｉｄｉｕｍ）ｄｉｆｆｉｃｉｌｅ）に対する免疫応答を誘発するための免疫原性組成物および方法
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物
WO2024196707A2 (en) * 2023-03-17 2024-09-26 The Board Of Trustees Of The University Of Illinois Chimeric antibody molecules based on tetrameric teleost immunoglobulin m
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
WO2025257712A1 (en) * 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
AU668092B2 (en) 1991-04-22 1996-04-26 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
ES2199227T5 (es) 1993-03-29 2007-12-01 Pfizer Inc. Vacunas clostridiales multicomponente que usan adyuvantes de saponina.
JPH10505358A (ja) 1994-09-06 1998-05-26 ギャラゲン・インコーポレイテッド クロストリジウム・ディフィシル関連疾患の治療処置
EP0796326A4 (en) 1994-10-24 2000-01-19 Ophidian Pharm Inc VACCINE AND ANTITOXIN FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASE
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
EP0877623A1 (en) 1995-07-07 1998-11-18 Oravax, Inc. Intranasal vaccination against gastrointestinal disease
WO1997002836A1 (en) 1995-07-07 1997-01-30 Oravax, Inc. Clostridium difficile toxins as mucosal adjuvants
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
AU753087B2 (en) 1996-07-12 2002-10-10 First Opinion Corporation Computerized medical diagnostic and treatment advice system including network access
ES2224273T3 (es) 1996-09-30 2005-03-01 University Of Arkansas Metodo para producir inmunidad activa por medio de un conjugado de vacuna.
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
AU754270B2 (en) 1997-10-20 2002-11-07 Sanofi Pasteur Biologics, Llc Passive immunization against clostridium difficile disease
CA2365915C (en) 1999-04-09 2015-11-24 Techlab, Inc. Recombinant toxin a/toxin b vaccine against clostridium difficile
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
CZ20023662A3 (cs) * 2000-05-04 2003-04-16 President And Fellows Of Harvard College Sloučeniny a způsoby léčení a prevence bakteriální infekce
CA2450783A1 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
US7226597B2 (en) 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
KR101052996B1 (ko) * 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
BRPI0506917A (pt) 2004-01-16 2007-06-05 Dow Global Technologies Inc expressão de proteìnas de mamìferos em pseudomonas fluorescens
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
PL2857418T3 (pl) 2004-02-06 2017-10-31 Univ Massachusetts Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1987361A4 (en) * 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
RU2561673C2 (ru) * 2006-03-30 2015-08-27 Эмбрекс, Инк. Способы и композиции для вакцинации домашней птицы
US8852600B2 (en) * 2006-06-08 2014-10-07 The Rockefeller University Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
WO2008024769A2 (en) 2006-08-21 2008-02-28 Raven Biotechnologies, Inc. Intensified perfusion production method
US7775167B2 (en) 2006-08-22 2010-08-17 Monsanto Technology Llc Custom planter and method of custom planting
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
JP5164970B2 (ja) * 2007-03-02 2013-03-21 パナソニック株式会社 音声復号装置および音声復号方法
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
CN101855336B (zh) * 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
WO2009139919A2 (en) 2008-05-15 2009-11-19 Tufts University Methods for diagnosis of clostridium diffcile and methods and vectors for recombinant toxin expression
EP2310045A1 (en) 2008-06-25 2011-04-20 Novartis AG Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
WO2010017383A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2010036826A1 (en) 2008-09-24 2010-04-01 Sanofi Pasteur Biologics Co. Methods and compositions for increasing toxin production
CN102264381B (zh) 2008-10-01 2014-07-09 美国政府(由卫生和人类服务部的部长所代表) 提供对疟原虫的长效免疫应答的用于疟疾的多组分疫苗
US10369204B2 (en) * 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
KR20110100189A (ko) 2008-12-03 2011-09-09 베링거잉겔하임베트메디카게엠베하 백신 생산 방법
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
GB0901001D0 (en) * 2009-01-22 2009-03-04 Univ Nottingham Methods
CA2752815A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
JP2013503198A (ja) 2009-08-27 2013-01-31 シナプティック リサーチ，リミテッド ライアビリティ カンパニー 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
CA2782406A1 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101870978A (zh) * 2010-03-23 2010-10-27 王世霞 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗
BR112012024898A2 (pt) 2010-03-30 2015-10-06 Pfenex Inc expressão de nível elevado de proteínas recombinantes de toxinas
US8765399B2 (en) 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
CN103957931B (zh) * 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
CA2817579A1 (en) * 2010-11-12 2012-04-14 Reflexion Pharmaceuticals, Inc. Gb1 peptidic libraries and compounds, and methods of screening the same
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
ES2615737T3 (es) 2011-05-27 2017-06-08 Glaxosmithkline Biologicals S.A. Composición inmunogénica
US9770500B2 (en) * 2011-05-31 2017-09-26 The Board Of Regents Of The University Of Texas System S-nitrosylation of glucosylating toxins and uses therefor
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR112015004629A2 (pt) 2012-09-19 2017-11-21 Novartis Ag polipeptídeos de clostridium difficile como vacinas
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2925362A4 (en) 2012-11-28 2016-07-20 Cnj Holdings Inc ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
WO2014086787A1 (en) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
WO2014144567A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
WO2014165608A1 (en) 2013-04-02 2014-10-09 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
CN105611942A (zh) 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法
EP3060246A4 (en) 2013-10-23 2017-08-16 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK1259103A1 (zh) 2015-11-17 2019-11-22 Pfizer Inc. 用於在细菌细胞培养物中生产多糖的培养基和发酵方法
MA44252A (fr) 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
EP3595709A4 (en) 2017-03-15 2020-12-23 Novavax, Inc. METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE
US10577665B2 (en) 2017-09-05 2020-03-03 Mcmaster University Aptamers for clostridium difficile detection
EP3687570A1 (en) 2017-09-28 2020-08-05 Pfizer Inc Compositions and methods for eliciting an immune response against clostridium difficile
JP6704173B2 (ja) 2019-09-26 2020-06-03 パナソニックＩｐマネジメント株式会社 開閉器及び分電盤

Also Published As

Publication number Publication date
RU2013145170A (ru) 2015-06-27
US20150307563A1 (en) 2015-10-29
TWI804717B (zh) 2023-06-11
US10597428B2 (en) 2020-03-24
CN111647059B (zh) 2023-11-28
USRE48862E1 (en) 2021-12-28
SI3505531T1 (sl) 2024-02-29
TW201932481A (zh) 2019-08-16
US8481692B2 (en) 2013-07-09
US20200095290A1 (en) 2020-03-26
ES2968629T3 (es) 2024-05-13
CN107022532B (zh) 2021-05-04
AU2020230248B2 (en) 2022-12-01
MY182429A (en) 2021-01-25
US20190202873A1 (en) 2019-07-04
USRE46518E1 (en) 2017-08-22
PH12013502178A1 (en) 2014-01-13
SG10201602668VA (en) 2016-05-30
SG10201911993UA (en) 2020-02-27
EP4365196A3 (en) 2024-08-07
IL273231B (en) 2021-08-31
WO2012143902A1 (en) 2012-10-26
IL255345B (en) 2021-05-31
US9187536B1 (en) 2015-11-17
DK2699587T3 (da) 2019-08-05
FI3549949T3 (fi) 2024-01-30
US20230391835A1 (en) 2023-12-07
SA115360697B1 (ar) 2016-04-05
PE20181334A1 (es) 2018-08-21
PL2699587T3 (pl) 2019-12-31
BR122019017005B1 (pt) 2022-03-29
PT2699587T (pt) 2019-09-05
SG194132A1 (en) 2013-11-29
EP4365196A2 (en) 2024-05-08
IL270779B2 (en) 2024-09-01
IL255345A0 (en) 2017-12-31
US20130330371A1 (en) 2013-12-12
IL228944A (en) 2017-11-30
TWI671313B (zh) 2019-09-11
TW202041525A (zh) 2020-11-16
JP5917682B2 (ja) 2016-05-18
IL273231A (en) 2020-04-30
USRE48863E1 (en) 2021-12-28
PH12013502178B1 (en) 2018-11-09
PT3549949T (pt) 2024-02-02
AU2012245904A1 (en) 2013-10-17
BR112013027229B1 (pt) 2020-10-27
US10774117B2 (en) 2020-09-15
EP3549949B1 (en) 2023-11-29
HUE047085T2 (hu) 2020-04-28
US9745354B2 (en) 2017-08-29
JP2017125030A (ja) 2017-07-20
EP3505531B1 (en) 2023-11-15
AU2017261465B2 (en) 2018-10-04
BR112013027229A2 (pt) 2016-11-29
IL270779A (en) 2020-01-30
IL265510B (en) 2021-05-31
AU2017261465A1 (en) 2017-11-30
IL265510A (en) 2019-05-30
IL254418A0 (en) 2017-11-30
JP2016117745A (ja) 2016-06-30
TW201302780A (zh) 2013-01-16
JP2014514318A (ja) 2014-06-19
CN111647059A (zh) 2020-09-11
JP2018052938A (ja) 2018-04-05
JP2019052149A (ja) 2019-04-04
TWI815599B (zh) 2023-09-11
EP2699587B1 (en) 2019-07-03
PE20141029A1 (es) 2014-09-04
US20130244307A1 (en) 2013-09-19
MY168205A (en) 2018-10-15
US11535652B2 (en) 2022-12-27
KR20130140206A (ko) 2013-12-23
CN103619871B (zh) 2016-12-14
TWI701257B (zh) 2020-08-11
RU2592686C2 (ru) 2016-07-27
DK3549949T5 (da) 2024-09-02
AU2019246878A1 (en) 2019-10-31
JP2022126822A (ja) 2022-08-30
DK3549949T3 (da) 2023-12-18
US20120269841A1 (en) 2012-10-25
AU2019246878B2 (en) 2020-09-10
SA115360698B1 (ar) 2016-04-27
AU2016202903B2 (en) 2017-11-30
MX347521B (es) 2017-04-27
RU2754446C2 (ru) 2021-09-02
ZA201307818B (en) 2014-06-25
IL254440A0 (en) 2017-11-30
IL270779B1 (en) 2024-05-01
CO6801643A2 (es) 2013-11-29
AU2012245904B2 (en) 2016-04-21
AU2018201296A1 (en) 2018-03-15
HRP20240042T1 (hr) 2024-03-29
IL254418B (en) 2019-12-31
AU2016202903A1 (en) 2016-05-26
RU2015154443A3 (enExample) 2019-05-22
USRE46376E1 (en) 2017-04-25
SA112330472B1 (ar) 2015-11-02
US8900597B2 (en) 2014-12-02
SI2699587T1 (sl) 2019-08-30
IL254440B (en) 2019-12-31
MX391236B (es) 2025-03-21
ES2742823T3 (es) 2020-02-17
EP3505531A1 (en) 2019-07-03
TWI650329B (zh) 2019-02-11
CA2832712C (en) 2018-08-28
AU2020230248A1 (en) 2020-10-01
HUE065594T2 (hu) 2024-06-28
CN103619871A (zh) 2014-03-05
PL3505531T3 (pl) 2024-03-11
JP2021130692A (ja) 2021-09-09
HRP20231631T1 (hr) 2024-03-15
MX385834B (es) 2025-03-18
EP3549949A1 (en) 2019-10-09
AR086199A1 (es) 2013-11-27
JP2018135345A (ja) 2018-08-30
CN107022532A (zh) 2017-08-08
MX2013012344A (es) 2013-11-20
IL245047A0 (en) 2016-05-31
US20170313749A1 (en) 2017-11-02
CA2832712A1 (en) 2012-10-26
US20150125927A1 (en) 2015-05-07
KR101667837B1 (ko) 2016-10-20
IL228944A0 (en) 2013-12-31
JP6097853B2 (ja) 2017-03-15
SI3549949T1 (sl) 2024-02-29
TWI686402B (zh) 2020-03-01
TW201932480A (zh) 2019-08-16
RU2015154443A (ru) 2019-01-17
ES2969952T3 (es) 2024-05-23
EP2699587A1 (en) 2014-02-26
TW202320843A (zh) 2023-06-01
JP6321239B2 (ja) 2018-05-09
JP6892425B2 (ja) 2021-06-23
JP6735784B2 (ja) 2020-08-05
JP7097478B2 (ja) 2022-07-07
TW201806967A (zh) 2018-03-01
PL3549949T3 (pl) 2024-04-08
US8557548B2 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
NZ616035A (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof
MX379863B (es) Composiciones y metodos relacionados con una toxina mutante de clostridium difficile
EP3892709A3 (en) Variants and compositions comprising variants with high stability in presence of a chelating agent
MX2014000989A (es) Composiciones detergentes.
MX2012012913A (es) Productos de consumo con variantes de la proteasa.
GB2509284A (en) Endoglycosidase from streptococcus pyogenes and methods using it
MX2009005655A (es) Composiciones y usos de un polipeptido alfa-amilasa del bacilo de la especie 195.
NZ703378A (en) Degradable clostridial toxins
MX2013012690A (es) Composiciones y metodos que comprenden variantes de proteasa serina.
MX338479B (es) Microorganismos thraustochytrid modificados.
PH12014500207B1 (en) Biocontrol of nematodes
MX346200B (es) Composicion inmunogenica.
IN2015DN01653A (enExample)
EP2231697A1 (en) Improved chimeric meganuclease enzymes and uses thereof
IN2014CN04131A (enExample)
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
GB2452892A (en) Process for culturing bacteria of the piscirickettsia genus
MX2009005117A (es) Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.
AU2014370874A1 (en) Improved beta-fructofuranosidase
MY182066A (en) Mutein, method for producing said mutein, gene encoding said mutein, recombinant vector and plant bearing said gene, method for controlling amount of mevalonic acid produced and amount of isoprenoid produced, method for controlling 3-hydroxy-3-methylglutaryl-coa reductase activity
WO2017174769A3 (en) Detergent compositions and uses of the same
MY155734A (en) Polishing composition for glass hard disk substrate
MY162031A (en) Modified thermostable enzyme and method
WO2013101724A3 (en) Inhibition of clostridium difficile toxins

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 APR 2019 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20160715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2020 BY THOMSON REUTERS

Effective date: 20190319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2021 BY THOMSON REUTERS

Effective date: 20200317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2022 BY THOMSON REUTERS

Effective date: 20210313

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2023 BY THOMSON REUTERS

Effective date: 20220308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2024 BY THOMSON REUTERS

Effective date: 20230307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2025 BY THOMSON REUTERS

Effective date: 20240305

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2026 BY THOMSON REUTERS

Effective date: 20250307